Calcimimetic Prescriptions in Fee-for-Service Medicare Beneficiaries Undergoing Dialysis
The results of this longitudinal cohort study showed that after transitioning calcimimetic coverage from Part D to Part B via TDAPA, calcimimetic prescriptions increased in a graded manner, with the largest increases experienced by patients previously subject to the highest out-of-pocket prescription drug costs. Medicare's TDAPA policy has the potential to expand access to medications for patients.
Authors
- Jillian S. Caldwell (ORCID: https://orcid.org/0000-0003-4645-6858)
- Glenn M. Chertow (ORCID: https://orcid.org/0000-0002-7599-0534)
- Xingxing S. Cheng (ORCID: https://orcid.org/0000-0002-0542-8749)
- Eran Bendavid (ORCID: https://orcid.org/0000-0002-8364-4711)
- Darius Lakdawalla (ORCID: https://orcid.org/0000-0001-5934-8042)
- Eugene Lin (ORCID: https://orcid.org/0000-0002-3559-5134)
Institutions
- University of Southern California (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1001/jamahealthforum.2025.0452
- Citations
- 3
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.29
Funders
- American Society of Nephrology
- American Kidney Fund
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases